Acne Patents (Class 514/859)
  • Patent number: 11878069
    Abstract: Provided are skincare compositions that include a bactericide, one or more surfactants, water, and optionally saturated fatty acid. The composition may include a bactericide, surfactants (e.g., anionic and/or zwitterionic), saturated fatty acid, and no more than about 50 wt % water. Alternatively, the composition may include a bactericide, surfactants (e.g., anionic and/or nonionic), and at least about 50 wt % water. Commonly, the skincare compositions may include benzoyl peroxide and goat milk. The compositions may be used for various applications including cleaning the skin and as a shaving cream.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: January 23, 2024
    Assignee: Dual-Shave LLC
    Inventors: Nisan David Lamden, Neil Badlani
  • Patent number: 8951775
    Abstract: The present invention relates to the cosmetic use of an effective amount of at least one probiotic microorganism and/or a fraction thereof and/or a metabolite thereof, as an agent for treating and/or preventing oily skin or skin with an oily tendency and the associated skin disorders.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: February 10, 2015
    Assignees: L'Oreal, Nestec SA
    Inventors: Isabelle Castiel, Audrey Gueniche
  • Patent number: 8921423
    Abstract: Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: December 30, 2014
    Assignee: Galderma Research & Development
    Inventors: Michael Graeber, Janusz Czernielewski
  • Patent number: 8853264
    Abstract: The present invention relates to the use of lignan compounds for treating or preventing an inflammatory disease. More particularly, it relates to a method for preventing or treating an inflammatory disease, comprising administering to a subject in need thereof an effective amount of macelignan represented by Chemical Formula I or a pharmaceutically acceptable salt thereof. The lignan compound has the effect of inhibiting inflammatory reactions by inhibiting the production or expression of inflammation mediators NO, iNOS, PGE2, COX-2 and TNF-? and by treating or preventing inflammatory disease in vivo. Accordingly, the lignan compound or a Myristica fragrans extract will be highly useful for the treatment or prevention of an inflammatory disease.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: October 7, 2014
    Assignees: Newtree Industry Co., Ltd.
    Inventors: Jae-Kwan Hwang, Do-Un Kim, Jae-Youn Chung, Hee-Chul Chung, Kyu-Lee Han
  • Patent number: 8846646
    Abstract: The invention relates to an unexpected discovery that propylene glycol is highly effective at killing or inhibiting Propionibacterium acnes in a mammalian skin disorder, as well as to the use of propylene glycol and salicylic acid in a skin-disorder treatment. This invention also relates to compositions containing propylene glycol alone or in combination with salicylic acid for use in killing or inhibiting Propionibacterium acnes.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: September 30, 2014
    Assignee: Winlind Skincare, LLC
    Inventor: Win L Chiou
  • Patent number: 8809305
    Abstract: A regimen for the safe and effective long-term treatment of acne vulgaris entails topically applying onto the affected skin area of a subject afflicted therewith, for a period of time of at least four (4) months, e.g., for at least twelve (12) months and advantageously on a daily basis and preferably once a day, a thus effective amount of a topical medicament containing adapalene and benzoyl peroxide, formulated into a pharmaceutically acceptable medium therefor.
    Type: Grant
    Filed: July 29, 2009
    Date of Patent: August 19, 2014
    Assignee: Galderma Research & Development
    Inventors: Michael Graeber, Yin Liu, Barbara Gore
  • Patent number: 8795635
    Abstract: The present invention relates to stable substantially non-aqueous, non-alcoholic, non-silicone, foamable carrier compositions comprising petrolatum or mixtures thereof, at least one foam agent, at least one propellant, and with and without the addition of an active agent. The formulations may contain a solvent substantially miscible therein. The present invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject in need thereof, comprising administering the above-mentioned compositions to an afflicted target site of said mammalian subject.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: August 5, 2014
    Assignee: Foamix Ltd.
    Inventors: Dov Tamarkin, Doron Friedman, Enbal Ziv, Meir Eini, Tal Berman, Jorge Danziger, Rita Keynan, David Schuz
  • Patent number: 8784780
    Abstract: Described herein are high oil-content emulsions and compositions for the treatment of inflammatory skin disorders. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. The emulsions or compositions may comprise active agents, such as corticosteroids. Also described are methods of treating inflammatory skin disorders, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: July 22, 2014
    Assignee: Precision Dermatology, Inc.
    Inventors: Ronald M. Gurge, Mark W. Trumbore, Lisa Chin, Poonam S. Hirani
  • Patent number: 8785420
    Abstract: Acne lesions, whether of inflammatory and/or non-inflammatory type, are simultaneously or sequentially treated and their number reduced, via daily topical regimen, with the combination or association of adapalene or pharmaceutically acceptable salt thereof and benzoyl peroxide (BPO).
    Type: Grant
    Filed: January 17, 2012
    Date of Patent: July 22, 2014
    Assignee: Galderma Research & Development
    Inventors: Marie-Line Abou Chacra Vernet, Denis Gross, Christian Loesche, Michel Poncet
  • Patent number: 8771759
    Abstract: Provided, among other things, is a method of treating or ameliorating an indication of non-mucosal topical tissue comprising periodically applying to such disease affected tissue a composition comprising: an effective amount of an appropriate composition of herbal bioactive comprising active(s) of one or more of Sambucus nigra, Centella asiatica or Echinacea purpurea, and an effective amount of a quaternary ammonium surfactant.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: July 8, 2014
    Assignee: Izun Pharmaceuticals, Inc.
    Inventors: William Zev Levine, Aron Jay Saffer, Gabriel Nussbaum
  • Patent number: 8729127
    Abstract: Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: May 20, 2014
    Assignee: Galderma Research & Development
    Inventors: Michael Graeber, Janusz Czernielewski
  • Patent number: 8725236
    Abstract: A method for demonstrating pre-emergent pimples is disclosed. The method includes providing a camera having a 25 mm macro lens and a linear polarizing filter including from 10 to 50 narrow band filters in the spectral range of 400-970 nm, and a light source having a linear polarizer oriented vertical to a polarization plane of the camera polarizer; taking a sequence of images of the face of a subject with the camera; creating an erythema map of the imaged area using oxy-hemoglobin values at each corresponding pixel; taking a visible-light image of the face of the subject; and comparing the images to see pre-emergent pimples. The method enables consumers to see pre-emergent pimples and treat them, which results in preventing the pimples from emerging or reducing the emergence of the pimples.
    Type: Grant
    Filed: March 2, 2007
    Date of Patent: May 13, 2014
    Assignee: Johnson & Johnson Consumer Companies, Inc.
    Inventors: Nikiforos Kollias, Georgios N. Stamatas
  • Patent number: 8709385
    Abstract: Pharmaceutical or cosmetic compositions and methods for their use are provided comprising water and a surfactant polymer system comprising a Poloxamer at a concentration of about 0.1% to about 15% by weight; wherein when the Poloxamer is between about 0.1% to about 5% Poloxamer. The composition can further comprise a supporting agent comprising a non-ionic surface active agent or a supporting agent comprising a non surfactant polymer or polysaccharide and an active agent, where the Poloxamer is capable of fixing the composition on delivery to a body surface. There are further provided therapeutic cell compositions and their uses.
    Type: Grant
    Filed: July 14, 2010
    Date of Patent: April 29, 2014
    Assignee: Foamix Ltd.
    Inventors: Dov Tamarkin, Alex Besonov, Tal Berman, David Schuz, Elana Gazal
  • Patent number: 8703820
    Abstract: Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
    Type: Grant
    Filed: October 12, 2010
    Date of Patent: April 22, 2014
    Assignee: Galderma Research & Development
    Inventors: Michael Graeber, Janusz Czernielewski
  • Patent number: 8673356
    Abstract: The present invention relates to stable fixed dose topical formulations comprising an antiacne agent and an antibiotic, which exhibit storage stability at a temperature of about 40° C. and relative humidity of about 75% for a period of at least 3 months. Particularly, the present invention relates to stable fixed dose topical formulations comprising therapeutically effective amounts of (a) adapalene-containing microspheres and (b) clindamycin, a process for their preparation thereof and their use for the treatment of acne.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: March 18, 2014
    Assignee: Glenmark Pharmaceuticals Limited
    Inventors: Ulhas Rameshchandra Dhuppad, Nitin Babulal Bhamre, Sunil Sudhakar Chaudhari, Girish Ramakrishna Trivedi, Akhilesh Dayanand Sharma, Prashant Dongre
  • Patent number: 8653140
    Abstract: Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: February 18, 2014
    Assignee: Galderma Research & Development
    Inventors: Michael Graeber, Janusz Czernielewski
  • Patent number: 8642646
    Abstract: The present invention relates to a method and composition for treating acne using lignan compounds represented by Formula 1. More particularly, the invention relates to an antibacterial composition against acne-causing bacteria, containing lignan compounds represented by Formula 1, as well as a method for treating acne using the same. The lignan compounds represented by Formula 1 are excellent not only in the antibacterial activity of inhibiting the growth of acne-causing bacteria, but also in thermal stability. Accordingly, the lignan compounds may be useful as antibacterial agents against the acne-causing bacteria, and acne treatment agents.
    Type: Grant
    Filed: January 7, 2005
    Date of Patent: February 4, 2014
    Assignees: New Tree Industry Co., Ltd.
    Inventors: Jae-Kwan Hwang, Jae-Youn Chung, Hee-Chul Chung, Kyung-Min Park
  • Patent number: 8609718
    Abstract: Disclosed is a novel use of phytosphingosine. More particularly, disclosed are a composition for preventing or treating hyper-proliferative skin diseases comprising pachastrissamine as an active ingredient, a use of pachastrissamine or a pharmaceutically acceptable salt thereof for preparing a preventing/therapeutic agent of hyper-proliferative skin diseases, and a method for treating hyper-proliferative skin diseases administering an effective amount of pachastrissamine or a pharmaceutically acceptable salt thereof to a subject in need thereof. The pachastrissamine inhibits the degradation of FoxO3a protein and increases the expression of FoxO3a protein. Thus, the inventive pharmaceutical composition has a preventing of treating effect on hyper-proliferative diseases by inducing apoptosis of hyper-proliferative cells and inhibiting the cell cycle.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: December 17, 2013
    Assignee: Catholic University Industry Academy Cooperation Foundation
    Inventors: Dong Heon Shin, Tae Yoon Kim
  • Patent number: 8604047
    Abstract: Methods and compositions are described for the treatment of very severe acne vulgaris, including nodulocystic acne and conglobate acne. Compounds which inhibit either or both type 1 and type 2 isoforms of steroid 5?-reductase are administered daily in either oral or topical formulations to patients suffering from severe forms of acne vulgaris. Very high dosages of such compounds can effectively be administered oral just once a week and be successful.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: December 10, 2013
    Assignee: Elorac, Inc.
    Inventor: Joel E. Bernstein
  • Patent number: 8591876
    Abstract: Provided herein are methods of using gaseous nitric oxide and/or at least one nitric oxide source to or decrease sebum production in the skin of a subject. In some embodiments, the nitric oxide source includes small molecule and/or macromolecular NO-releasing compounds.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: November 26, 2013
    Assignee: Novan, Inc.
    Inventors: Susanne Bauman, Nathan A. Stasko
  • Patent number: 8592380
    Abstract: Described herein are emulsions and compositions for the treatment of acne vulgaris. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. The emulsions or compositions may comprise clindamycin phosphate and a buffer salt, and may exhibit decreased rates of clindamycin phosphate hydrolysis. Also described are methods of treating acne vulgaris, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition.
    Type: Grant
    Filed: March 22, 2011
    Date of Patent: November 26, 2013
    Assignee: Precision Dermatology, Inc.
    Inventors: Mark W. Trumbore, Wendy Schilling, Ravi K. Varanasi
  • Patent number: 8586008
    Abstract: The present invention provides various pharmaceutically active topical delivery compositions. In particular, compositions of the present invention are present in a pressurized container comprising a quick-breaking alcoholic foaming agent, such that when the composition is released, i.e., dispensed, from the pressurized container, a quick-breaking temperature sensitive foam is formed. In addition, the present invention provides various aspects related to such compositions, including methods for modulating a foam characteristic, methods for improving the shelf-life of a pharmaceutically active compound, methods for the percutaneous treatment of various diseases, infections, and illnesses, and methods for evaluating foam characteristics.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: November 19, 2013
    Assignee: Stiefel West Coast, LLC
    Inventors: Albert Zorko Abram, Lilian Fuchshuber
  • Patent number: 8580317
    Abstract: This invention provides anti-acne kits that are useful for treating acne, especially severe cases of acne. The anti-acne kits include a vasoconstrictor and an anti-acne agent, and optionally one or more of a a skin lightening therapeutic, a sealing layer, a skin cleanser, an astringent, a skin penetration enhancer, a sunscreen, and nutritional supplements that promote healing of acne lesions. This invention also provides methods for treating acne using a vasoconstrictor in conjunction with an anti-acne agent.
    Type: Grant
    Filed: March 30, 2006
    Date of Patent: November 12, 2013
    Assignee: Revance Therapeutics, Inc.
    Inventors: Jacob M. Waugh, Jae Hoon Lee
  • Patent number: 8529970
    Abstract: Materials with high levels of unsaponifiable matter, such as extracts from plants, produce hydrolysates with unique properties. Properties that are sought in traditional saponification of natural oils are a result of low levels of unsaponifiables. These properties include high levels of aqueous surfactant activity, water-solubility or ready water-dispersability, activity as foaming agents, and the like. An objective of traditional saponification processes is to increase the water-solubility and surfactant activity of naturally occurring materials. It has been found that the application of a hydrolysis process to materials, particularly materials with a high level of unsaponifiables (e.g., at least 6 weight percent of the material), produces a product with properties significantly different from those products resulting from the conventional saponification of materials with less than 6 weight percent of unsaponifiables.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: September 10, 2013
    Assignee: International Flora Technologies, Ltd.
    Inventors: James H. Brown, Lee Roy Copeland, Robert Kleiman, Melanie K. Cummings, Sambasivarao Koritala
  • Patent number: 8513225
    Abstract: Disclosed herein is a composition containing a high concentration of PG is unexpectedly capable of quickly killing other bacteria, fungi, and/or virus in vitro that is indicative of its potential high efficacy in treating various skin infection. Embodiments disclosed herein relate to a composition and method for effective topical treatment of inflammatory skin lesions in mammals, comprising of a high concentration of propylene glycol alone, or in combination with an astringent. The PG at high concentrations can be regarded as an extremely effective, safe, topical, universal, microbicide.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: August 20, 2013
    Assignee: Winlind Skincare, LLC
    Inventor: Win L Chiou
  • Patent number: 8512718
    Abstract: A pharmaceutical or cosmetic carrier or composition for topical application characterized by rheological properties which render the carrier or composition semi-solid at rest and a liquid upon application of shear forces thereto. The composition or carrier are prepared by mixing 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent, by weight, wherein at least one of them has therapeutic or cosmetic benefits, in the presence or absence of a biologically active substance.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: August 20, 2013
    Assignee: Foamix Ltd.
    Inventors: Meir Eini, Dov Tamarkin
  • Patent number: 8501202
    Abstract: A topical composition for the treatment of mammalian skin dermatoses comprising a sulfacetamide or a derivative thereof and at least 1 sunscreen wherein the sunscreen is present in a sufficient amount to produce a sun protection factor of about 1.6 to about 20.6. Also provided is a method of treating mammalian dermatoses by administering a topical composition comprising a sulfacetamide or a derivative thereof and at least 1 sunscreen wherein the sunscreen is present in a sufficient amount to produce a sun protection factor of about 1.6 to about 20.6.
    Type: Grant
    Filed: January 26, 2006
    Date of Patent: August 6, 2013
    Assignee: Aqua Pharmaceuticals, LLC
    Inventor: Charles W. Stiefel
  • Patent number: 8492366
    Abstract: The solubility in solvent media, notably alcoholic media, of the beta-hydroxy acids (“BHAs”), notably the chemical skin peeling agent salicylic acid, is markedly enhanced by solubilizing same in the presence of at least one alpha-hydroxy acid (“AHA”); higher potency, more concentrated BHA skin peel products are thus formulated.
    Type: Grant
    Filed: February 26, 2003
    Date of Patent: July 23, 2013
    Assignee: Societe L'Oreal S.A.
    Inventors: Marc Cornell, Hani Fares, Sidney Peter Foltis, Isabelle Hansenne
  • Patent number: 8475770
    Abstract: The present subject matter provides foamable suspension gels that foam after release from a container. The foamable suspension gels contain at least one pharmaceutically active agent that is sparingly soluble to insoluble in water, a second pharmaceutically active agent, and optionally a third active agent.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: July 2, 2013
    Assignee: Stiefel Research Australia Pty Ltd
    Inventors: Albert Zorko Abram, Lilian Fuchshuber
  • Patent number: 8466128
    Abstract: The present invention provides compositions suitable for topical administration to a mammalian subject including sodium hyaluronate and a pharmaceutically acceptable excipient. The present invention also provides methods for malting and using the same.
    Type: Grant
    Filed: January 29, 2008
    Date of Patent: June 18, 2013
    Assignee: Cypress Pharmaceuticals, Inc.
    Inventor: Robert Lewis
  • Patent number: 8465763
    Abstract: The present invention relates to the use of 3?-hydroxychlormadinone acetate (17?-acetoxychloropregna-4,6-dien-3?-ol-20-one) and/or 3?-hydroxychlormadinone acetate (17?-acetoxychloropregna-4,6-dien-3?-ol-20-one) for producing a medicament for treating skin, preferably human skin by means of topical application, and to a pharmaceutical or cosmetic composition containing 3?-hydroxychlormadinone acetate and/or 3?-hydroxychlormadinone acetate.
    Type: Grant
    Filed: June 12, 2009
    Date of Patent: June 18, 2013
    Assignee: Richter Gedeon Nyrt.
    Inventors: Georg Schramm, Christa Kneip
  • Patent number: 8338484
    Abstract: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: December 25, 2012
    Assignee: Panmira Pharmaceuticals, LLC
    Inventors: John Howard Hutchinson, Brian Andrew Stearns, Yen Pham Truong
  • Patent number: 8309121
    Abstract: Compositions and nanoemulsions containing lipid nanocapsules dispersed in a hydrophilic phase, such nanocapsules including at least one avermectin compound, are useful for the treatment of dermatological pathologies, e.g., rosacea.
    Type: Grant
    Filed: April 10, 2009
    Date of Patent: November 13, 2012
    Assignee: Galderma S.A.
    Inventors: Lara Baudonnet, Claire Mallard
  • Patent number: 8207212
    Abstract: Methods for preventing damage to the epidermis during PDT induced using a pre-photosensitizing agent are provided. The methods of the present invention utilize spatial confinement to control formation of a photoactive species from a topically-applied pre-photosensitizing agent. In one embodiment, thermal inhibition is used to prevent the metabolism of a pre-photosensitizing agent in epithelial tissue surrounding a treatment site. In another embodiment, a chemical inhibitor can be applied to the epithelial tissue to inhibit the conversion of a pre-photosensitizing agent into a phototoxic species.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: June 26, 2012
    Assignee: The General Hospital Corporation
    Inventors: Richard Rox Anderson, Bernhard Ortel, Eliot F. Battle, Edwin K. Joe
  • Patent number: 8147875
    Abstract: The invention provides a method for the treatment of acne comprising orally administering to a person suffering from acne an effective amount of a whey protein fraction containing lactoferrin, and preferably containing further specific whey proteins. The lactoferrin is preferably native bovine lactoferrin and the whey protein fraction is administered at a level of between 10 mg and 2 g lactoferrin per patient per day.
    Type: Grant
    Filed: March 14, 2006
    Date of Patent: April 3, 2012
    Assignee: Campina Nederland Holding B.V.
    Inventors: Rick De Waard, Angela Loriann Walter
  • Patent number: 8147883
    Abstract: The invention concerns the use of at least a vegetable oil product selected among the group consisting of vegetable oil oleic distillates, vegetable oil unsaponifiable matters, vegetable oil furan lipids and mixtures thereof, as agents for increasing skin lipid synthesis, in particular lipids of the epidermal skin barrier, in or for preparing a composition containing a pharmaceutically or dermatologically acceptable medium. The use enables to prevent and/or treat deterioration of the skin barrier (dry skin, skin subjected to actinic radiation, ichthyosis, acne, xerosis, atopic dermatitis, sensitive skin, chafing and reactive skin, itching and the like).
    Type: Grant
    Filed: September 20, 2000
    Date of Patent: April 3, 2012
    Assignee: Laboratoires Expanscience
    Inventors: Philippe Msika, Antoine Piccirilli
  • Patent number: 8129362
    Abstract: Acne lesions, whether of inflammatory and/or non-inflammatory type, are simultaneously or sequentially treated and their number reduced, via daily topical regimen, with the combination or association of adapalene or pharmaceutically acceptable salt thereof and benzoyl peroxide (BPO).
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: March 6, 2012
    Assignee: Galderma Research & Development
    Inventors: Marie-Line Abou Chacra Vernet, Denis Gross, Christian Loesche, Michel Poncet
  • Patent number: 8080537
    Abstract: Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: December 20, 2011
    Assignee: Galderma Research & Development
    Inventors: Marie-line Abou-Chacra Vernet, Denis Gross, Christian Loesche, Michel Poncet
  • Patent number: 8071644
    Abstract: Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO.
    Type: Grant
    Filed: January 13, 2009
    Date of Patent: December 6, 2011
    Assignee: Galderma Research & Development
    Inventors: Marie-line Abou-Chacra Vernet, Denis Gross, Christian Loesche, Michel Poncet
  • Patent number: 8008345
    Abstract: There is provided a method for preventing, alleviating symptoms or treating a skin condition comprising topically administering to the skin of a subject a cosmetic or pharmaceutical topical formulation comprising an effective skin-penetrating amount of one or more phosphate derivatives of one or more electron transfer agents.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: August 30, 2011
    Assignee: Vital Health Sciences Pty. Ltd.
    Inventors: Simon Michael West, Robert J. Verdicchio, David Kannar, Otto H. Mills, Jr.
  • Patent number: 7985771
    Abstract: The invention relates to a method of treating with furanone derivatives and the pharmaceutically acceptable salts thereof, one or more conditions of the skin, in particular regulating skin condition, regulating signs of skin aging, treating a number of conditions such as contact dermatitis, skin irritation, rosacea, acne, psoriasis, and preventing and protecting skin tissue against age-related damage or damage resulting from insults such as harmful (UV) radiation or environmental pollution, stress and fatigue.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: July 26, 2011
    Assignee: Monsanto Technology LLC
    Inventors: Sekhar Boddupalli, Gail Walkinshaw, Bing Wang
  • Patent number: 7939567
    Abstract: The present invention relates to a method for providing bactericide or bacteriostatic, especially for treating disease due to bacterial infection. The method comprising administering a patient in need of such treatment a therapeutically effective amount of a compound of dextromethorphan or naloxone or a pharmaceutically acceptable salt or an analog thereof. The compound is applied to skin or mucosal surface of the patient. The invention also relates to a method of treating inflammation caused by suppressing secretion of TNF-?, IL-6, or MCP-1 from macrophage comprising administering a patient in need of such treatment a therapeutically effective amount of NADPH oxidase inhibitor.
    Type: Grant
    Filed: February 24, 2006
    Date of Patent: May 10, 2011
    Assignee: Blue Blood Biotech Corp.
    Inventors: Hua-Lin Wu, Guey-Yueh Shi
  • Patent number: 7868044
    Abstract: Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions.
    Type: Grant
    Filed: May 3, 2010
    Date of Patent: January 11, 2011
    Assignee: Galderma Research & Development
    Inventors: Michael Graeber, Janusz Czernielewski
  • Patent number: 7838558
    Abstract: Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
    Type: Grant
    Filed: April 15, 2008
    Date of Patent: November 23, 2010
    Assignee: Galderma Research & Development S.N.C.
    Inventors: Michael Graeber, Janusz Czernielewski
  • Patent number: 7834060
    Abstract: Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: November 16, 2010
    Assignee: Galderma Research & Development
    Inventors: Michael Graeber, Janusz Czernielewski
  • Patent number: 7829712
    Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where x, y, G, J, K, L, M, Q, W, V, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
    Type: Grant
    Filed: September 20, 2005
    Date of Patent: November 9, 2010
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Rajender Kamboj, Zaihui Zhang, Jianmin Fu, Serguei Sviridov, Sultan Chowdhury, Vishnumurthy Kodumuru
  • Patent number: 7785638
    Abstract: Disclosed herein an herbal acne control compositions comprising extracts of Swietenia mahagoni, Salix tetrasperma, Aloe vera and Curcuma longa and pharmaceutically acceptable excipients. Also disclosed are the methods of making the composition, formulating the same into different delivery systems and use thereof for the prevention of acne related skin disorders in human beings.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: August 31, 2010
    Assignee: Himalaya Global Holdings, Ltd
    Inventors: Shankar Kumar Mitra, Ekta Saxena, Uddagiri Venkanna Babu
  • Patent number: 7781410
    Abstract: The present invention features composition comprising a chalcone and the use thereof for treating acne and reducing the appearance of oil or pores on the skin, hair and scalp.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: August 24, 2010
    Assignee: Johnson & Johnson Consumer Companies, Inc.
    Inventors: Claude Saliou, Sekhar Boddupalli, Khalid Mahmood, Michael Anthonavage, Kelly Huang
  • Patent number: 7737181
    Abstract: Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions.
    Type: Grant
    Filed: July 28, 2006
    Date of Patent: June 15, 2010
    Assignee: Galderma Research & Development
    Inventors: Michael Graeber, Janusz Czernielewski
  • Patent number: 7687065
    Abstract: The present invention relates to a gel composition useful for skin care and protection comprising up to 80% w/w Dead Sea water (or similarly constituted water), solubilizers, gelling agents or viscosity modifiers and deionized water to complete up to 100%. Preferably, the composition is a clear liquid gel. The gel optionally comprises hydrophobic and/or hydrophilic active agents. In the composition of the present invention the hydrophobic active agents may be vegetable oils, free fatty acids or vitamins, or any combination thereof and the hydrophilic active agent may be humectants, ?-hydroxy acids, anti irritant agents, plant extracts, moisturizing agents or hydrolyzed plant proteins or any combination thereof. The gel may further comprise antioxidants and fragrances.
    Type: Grant
    Filed: December 17, 1998
    Date of Patent: March 30, 2010
    Assignee: Dead Sea Laboraories, Ltd.
    Inventors: Zeev Maor, Assia Kogan, Shlomo Magdassi, Shaul Yehuda